Trade 46

HOLD LLY

0 shares at $999.01 on 2026-05-15

Reasoning

Thesis #36 is the third consecutive playbook requesting LLY entry at $999.53 (at support). The playbook reasoning correctly notes that the summit binary risk justifying previous deferrals is now resolved. However, execution constraint applies: the account is ~95% cash with only $4.5K in long positions and $195.5K buying power available. The playbook correctly prioritizes AMAT (priority 1, $350 allocation) and MSFT (priority 3, $200 allocation), totaling $550 before LLY. Given formation-mode Rule #1 constraints ($200-$500 per position, max 0.5% buying_power), and the fact that Healthcare sector underperformed only marginally today (-1.1%) in a broad risk-off environment, the thesis rationale is sound but EXECUTION ORDER suggests LLY is deferred to allow higher-priority catalysts (AMAT post-summit clarity, MSFT Ackman validation) to settle first. Deferring LLY one more session is defensible given the priority sequencing and Rule #4 (avoid large positions in macro uncertainty). If deferred again in the next playbook without new BLOCKERS, thesis should be closed as expired per playbook instruction.

Thesis

LLY defensive pharma long — GLP-1/incretin franchise leader (Zepbound/Mounjaro) plus deep cardiometabolic pipeline; held as rate-shielded defensive-growth ballast. Partial profit-take was executed Aug 26 at the 10-15%+ band; remaining core managed on trail. FRESH POSITIVE CATALYSTS (Sep 22): LLY received full FDA approval for Inluriyo in ESR1-mutated breast cancer (regulatory/bullish), and the CEO said its oral GLP-1 Foundayo is winning ~1/3 of new oral GLP-1 scripts (product/bullish/high) — validating the oral-incretin land-grab against competitors. Offsetting overhang persists: renewed drug-pricing/Medicare scrutiny (most-favored-nation, CMS lab payment cuts). Net: franchise fundamentals strengthening; hold the retained core as ballast on trail, do not re-trim on the same band. (long, medium confidence)

Cited evidence

News

Macro